1.9 Health Promotion and Disease Prevention

Health Promotion and Disease Prevention

Advanced practice psychiatric nursing integrates health promotion and disease prevention into every clinical encounter. Individuals with Severe Mental Illness (SMI)—such as Schizophrenia, Bipolar I Disorder, and Recurrent Major Depressive Disorder—suffer a staggering premature mortality gap of 15 to 25 years compared to the general population. Crucially, the vast majority of these premature deaths are not caused by suicide or accidents, but by preventable medical comorbidities, primarily cardiovascular disease, metabolic syndrome, type 2 diabetes mellitus, and respiratory disease. This section details the public health prevention levels, cardiometabolic risk protocols, lifestyle neurobiology, and health equity frameworks essential for the ANCC PMHNP examination.

Public Health Framework: Three Levels of Prevention

PMHNPs must be adept at categorizing clinical interventions into the three classic public health prevention levels:

   +-------------------------------------------------------------------------+
   |                          PRIMARY PREVENTION                             |
   |  - Target: Healthy Population / Well Individuals                       |
   |  - Goal: Prevent disease ONSET (Decrease Incidence)                     |
   |  - Examples: Resilience training, suicide education, parenting classes |
   +------------------------------------+\------------------------------------
                                        |
                                        v
   +-------------------------------------------------------------------------+
   |                         SECONDARY PREVENTION                            |
   |  - Target: At-Risk Individuals / Asymptomatic Early Disease             |
   |  - Goal: EARLY SCREENING & Prompt Intervention (Decrease Prevalence)     |
   |  - Examples: PHQ-9 screening, CAGE/AUDIT, SGA metabolic bloodwork       |
   +------------------------------------+\------------------------------------
                                        |
                                        v
   +-------------------------------------------------------------------------+
   |                          TERTIARY PREVENTION                            |
   |  - Target: Chronically Ill Patients with Established Disease            |
   |  - Goal: Rehabilitation, Relapse Prevention, Reduce Disability          |
   |  - Examples: Assertive Community Treatment (ACT), Social Skills Groups |
   +-------------------------------------------------------------------------+

1. Primary Prevention

• Focus: Preventing the occurrence of a disease or mental health disorder before pathology initiates.
• Mechanism: Mitigating risk factors and fortifying protective biological, psychological, and environmental buffers.
• Goal: Lower the incidence (rate of new cases) of illness.
• Clinical Examples:
  • Community-wide suicide prevention gatekeeper training in high schools.
  • Stress management and mindfulness resilience programs for healthcare workers.
  • Perinatal maternal mental health home-visiting programs to prevent adverse childhood experiences (ACEs).
  • Folic acid supplementation in women of childbearing age to prevent neural tube defects.

2. Secondary Prevention

• Focus: Early detection, screening, and prompt intervention while disease is in early or subclinical stages to arrest progression.
• Mechanism: Identifying latent pathology through systematic screening protocols.
• Goal: Lower the prevalence (total active cases) by shortening disease duration and severity.
• Clinical Examples:
  • Administering the PHQ-9 (depression) or GAD-7 (anxiety) tools universally in primary care clinics.
  • Screening for unhealthy alcohol use using the AUDIT or CAGE questionnaires.
  • Baseline and periodic metabolic bloodwork (fasting lipid panel, HbA1c) in patients starting antipsychotics.
  • Screening for cognitive decline using the MoCA or MMSE in older adults with memory complaints.

3. Tertiary Prevention

• Focus: Managing established, chronic psychiatric or medical disease to prevent disability, reduce relapse rates, and restore maximal functional capacity.
• Mechanism: Psychosocial rehabilitation, tertiary pharmacotherapy monitoring, and multi-system support.
• Goal: Minimize morbidity, long-term disability, and tertiary complications.
• Clinical Examples:
  • Enrolling a patient with severe schizophrenia in an Assertive Community Treatment (ACT) team.
  • Psychosocial skills training and vocational rehabilitation for chronic psychiatric disorders.
  • Clozapine clinic monitoring for treatment-resistant schizophrenia to prevent hospital readmissions.
  • Cardiac rehabilitation following a myocardial infarction in a patient with major depression.

---

Cardiometabolic Risk & Antipsychotic Management

Second-Generation Antipsychotics (SGAs) are cornerstone treatments for psychotic and mood disorders, but carry significant cardiometabolic liability. Up to 40% of patients on chronic SGA therapy develop Metabolic Syndrome.

Antipsychotic Metabolic Risk Stratification:

• High Risk: Clozapine, Olanzapine
• Moderate Risk: Quetiapine, Risperidone, Paliperidone
• Low / Neutral Risk: Aripiprazole, Ziprasidone, Lurasidone, Cariprazine, Lumateperone

Diagnostic Criteria for Metabolic Syndrome (NCEP ATP III Criteria)

Diagnosed when a patient meets at least 3 out of the 5 following criteria:

1. Abdominal Obesity: Waist circumference $> 40$ inches ($102$ cm) in men, $> 35$ inches ($88$ cm) in women.
2. Elevated Triglycerides: $\ge 150$ mg/dL ($1.7$ mmol/L) or on drug treatment.
3. Reduced HDL Cholesterol: $< 40$ mg/dL ($1.03$ mmol/L) in men, $< 50$ mg/dL ($1.29$ mmol/L) in women.
4. Elevated Blood Pressure: Systolic $\ge 130$ mmHg and/or Diastolic $\ge 85$ mmHg, or on antihypertensive therapy.
5. Elevated Fasting Plasma Glucose: $\ge 100$ mg/dL ($5.6$ mmol/L) or on antidiabetic medication.

ADA / APA Consensus Monitoring Protocol

The American Diabetes Association (ADA) and American Psychiatric Association (APA) mandate the following monitoring schedule for all patients initiated on SGAs:

---

Lifestyle Medicine & Neurobiology

Lifestyle interventions are evidence-based, biological therapies that PMHNPs should prescribe alongside pharmacotherapy and psychotherapy.

1. Exercise Neuroscience

• Mechanism: Moderate aerobic exercise ($150$ minutes/week) stimulates the synthesis and release of Brain-Derived Neurotrophic Factor (BDNF) in the hippocampus. BDNF promotes neurogenesis, synaptic plasticity, and dendritic branching.
• Inflammatory Modulation: Exercise downregulates systemic pro-inflammatory cytokines (TNF-alpha, IL-6) and normalizes HPA axis tone.

2. Nutritional Psychiatry & Gut-Brain Axis

• The gastrointestinal tract produces over 90% of the body's serotonin. Diets high in refined sugars and ultra-processed foods induce gut dysbiosis, increasing intestinal permeability ("leaky gut") and systemic neuroinflammation. The Mediterranean diet (rich in omega-3 fatty acids, polyphenols, and fiber) correlates with a 25-35% lower risk of depression.

3. Tobacco Cessation & CYP1A2 Pharmacokinetics

• High Prevalence: Over 60-70% of individuals with schizophrenia smoke tobacco.
• CYP1A2 Enzyme Induction: Polycyclic aromatic hydrocarbons in tobacco smoke (NOT nicotine itself) are potent inducers of the hepatic CYP1A2 enzyme.
• Pharmacokinetic Impact: Smoking induces CYP1A2, accelerating the metabolism of Clozapine and Olanzapine, lowering their serum levels by 30-50%.
• Critical Exam Warning: When a patient taking clozapine or olanzapine stops smoking, CYP1A2 induction ceases. Serum medication levels will dramatically spike, placing the patient at high risk for toxicity (seizures, severe sedation, agranulocytosis risk with clozapine). PMHNPs must decrease the clozapine/olanzapine dose by 30-50% upon smoking cessation!

---

Social Determinants of Health (SDOH) & Health Equity

According to Healthy People 2030, SDOH account for up to 50-60% of health outcomes. The 5 core SDOH domains are:

1. Economic Stability (Poverty, employment, food security)
2. Education Access and Quality (Literacy, early childhood education)
3. Healthcare Access and Quality (Health insurance coverage, health literacy)
4. Neighborhood and Built Environment (Housing quality, crime rates, environmental hazards)
5. Social and Community Context (Social cohesion, discrimination, workplace stress)

PMHNPs must practice structural competency—recognizing how systemic policies and social structures create health inequities—and deliver trauma-informed, culturally responsive care.

---

Recovery and Resilience Promotion

ANCC Advanced Practice Skills also require recovery and resilience promotion—helping patients build meaningful lives beyond symptom reduction alone.

Recovery-Oriented Practice

Psychiatric recovery is a person-driven process of living a satisfying, hopeful, and contributing life even with ongoing symptoms. Core principles include:

• Hope and self-direction: Treatment goals reflect the patient's values (housing, work, relationships, spirituality), not only clinician-defined symptom scores.
• Strengths-based assessment: Identify protective factors, prior coping successes, and community supports rather than cataloguing deficits alone.
• Peer support and community inclusion: Link to peer specialists, Clubhouse/IPS supported employment models, and community resources that reduce isolation.
• Shared decision-making: Medications and psychotherapy are tools supporting recovery, not ends in themselves.

Resilience Promotion Strategies

Resilience is the capacity to adapt under adversity. PMHNPs promote resilience through:

• Skills training (problem-solving, emotion regulation, distress tolerance)
• Sleep, exercise, and social rhythm stabilization
• Trauma-informed care that avoids re-traumatization
• Building social connectedness and reducing loneliness
• Addressing SDOH barriers that undermine recovery (food, housing, transportation)

On exam scenarios, choose interventions that restore agency, role functioning, and protective factors—not only acute symptom suppression.